Description:

AMC-061 Response Evaluation Form (R61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Link:

https://clinicaltrials.gov/ct2/show/NCT00890747

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 6/24/17
Uploaded on:

June 24, 2017

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

HIV Cancer Sunitinib NCT00890747 AMC-061

This form is to be updated at each response assessment time point defined in the protocol. Please see protocol for guidelines for response evaluation

Header Module
mm/dd/yyyy
Complete Response
Complete response first observed (CR)
mm/dd/yyyy
Complete response confirmed (CR)
mm/dd/yyyy
Method of Evaluation
Morphologic Complete Remission
Morphologic Complete Remission (CR) First Observed
mm/dd/yyyy
Morphologic Complete Remission (CR) Confirmed
mm/dd/yyyy
Method of Evaluation
Complete Response, Unconfirmed
Complete Response, Unconfirmed (CRu) First Observed
mm/dd/yyyy
Complete Response, unconfirmed (CRu) confirmed
mm/dd/yyyy
Method of Evaluation
Morphologic Complete Remission With Incomplete Blood Count Recovery
Morphologic Complete Remission With Incomplete Blood Count Recovery (CRi) First Observed
mm/dd/yyyy
Morphologic Complete Remission With Incomplete Blood Count Recovery (CRi) Confirmed
mm/dd/yyyy
Method of Evaluation
Partial Response
Partial response first observed (PR)
mm/dd/yyyy
Partial response confirmed
mm/dd/yyyy
Method of Evaluation
Progressive Disease
Has the patient been diagnosed with relapsed/recurrent or progressive disease (If Yes, continue. Otherwise, stop)
mm/dd/yyyy
Please indicate site of progression/relapse